array(40) {
  [0]=>
  string(4) "7055"
  ["article_id"]=>
  string(4) "7055"
  [1]=>
  string(77) "ViiV Healthcare secures Japanese approval for Dovato to treat HIV-1 infection"
  ["article_title"]=>
  string(77) "ViiV Healthcare secures Japanese approval for Dovato to treat HIV-1 infection"
  [2]=>
  string(150) "The Japan Ministry of Health, Labour and Welfare (MHLW) has approved Dovato to treat HIV-1 infection in adults and adolescents above12 years of age wi"
  ["short_description"]=>
  string(150) "The Japan Ministry of Health, Labour and Welfare (MHLW) has approved Dovato to treat HIV-1 infection in adults and adolescents above12 years of age wi"
  [3]=>
  string(537) "
The Japan Ministry of Health, Labour and Welfare (MHLW) has approved Dovato to treat HIV-1 infection in adults and adolescents above12 years of age with a minimum of 
&#nl
The post ViiV Healthcare secures Japanese approval for Dovato to treat HIV-1 infection appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(537) "
The Japan Ministry of Health, Labour and Welfare (MHLW) has approved Dovato to treat HIV-1 infection in adults and adolescents above12 years of age with a minimum of 
&#nl
The post ViiV Healthcare secures Japanese approval for Dovato to treat HIV-1 infection appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(75) "https://www.pharmaceutical-business-review.com/news/viiv-healthcare-dovato/"
  ["blog_url"]=>
  string(75) "https://www.pharmaceutical-business-review.com/news/viiv-healthcare-dovato/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-16 20:18:46"
  ["create_at"]=>
  string(19) "2020-01-16 20:18:46"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7056"
  ["article_id"]=>
  string(4) "7056"
  [1]=>
  string(73) "Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer"
  ["article_title"]=>
  string(73) "Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer"
  [2]=>
  string(150) "As per the terms of the deal, the Japanese pharma company and Adaptimmune will select up to three targets for their collaboration and will co-develop "
  ["short_description"]=>
  string(150) "As per the terms of the deal, the Japanese pharma company and Adaptimmune will select up to three targets for their collaboration and will co-develop "
  [3]=>
  string(562) "
As per the terms of the deal, the Japanese pharma company and Adaptimmune will select up to three targets for their collaboration and will co-develop T-cell therapy candidates 
&#nl
The post Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(562) "
As per the terms of the deal, the Japanese pharma company and Adaptimmune will select up to three targets for their collaboration and will co-develop T-cell therapy candidates 
&#nl
The post Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(94) "https://www.pharmaceutical-business-review.com/news/deals/astellas-adaptimmune-t-cell-therapy/"
  ["blog_url"]=>
  string(94) "https://www.pharmaceutical-business-review.com/news/deals/astellas-adaptimmune-t-cell-therapy/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-16 20:18:46"
  ["create_at"]=>
  string(19) "2020-01-16 20:18:46"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7057"
  ["article_id"]=>
  string(4) "7057"
  [1]=>
  string(78) "BioMotiv and Atomwise sign AI partnership to transform therapeutic development"
  ["article_title"]=>
  string(78) "BioMotiv and Atomwise sign AI partnership to transform therapeutic development"
  [2]=>
  string(168) "The organizations will form co-owned, joint development companies (“JDCs”) that will integrate Atomwise’s AI technology and BioMotiv’s deep ex"
  ["short_description"]=>
  string(168) "The organizations will form co-owned, joint development companies (“JDCs”) that will integrate Atomwise’s AI technology and BioMotiv’s deep ex"
  [3]=>
  string(677) "
The organizations will form co-owned, joint development companies (“JDCs”) that will integrate Atomwise’s AI technology and BioMotiv’s deep expertise in preclinical and clinical development to translate innovative academic 
&#nl
The post BioMotiv and Atomwise sign AI partnership to transform therapeutic development appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(677) "
The organizations will form co-owned, joint development companies (“JDCs”) that will integrate Atomwise’s AI technology and BioMotiv’s deep expertise in preclinical and clinical development to translate innovative academic 
&#nl
The post BioMotiv and Atomwise sign AI partnership to transform therapeutic development appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(131) "https://www.pharmaceutical-business-review.com/news/biomotiv-and-atomwise-sign-ai-partnership-to-transform-therapeutic-development/"
  ["blog_url"]=>
  string(131) "https://www.pharmaceutical-business-review.com/news/biomotiv-and-atomwise-sign-ai-partnership-to-transform-therapeutic-development/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-16 20:18:47"
  ["create_at"]=>
  string(19) "2020-01-16 20:18:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7058"
  ["article_id"]=>
  string(4) "7058"
  [1]=>
  string(102) "Charles River, Takeda announce scientific collaboration to identify and develop preclinical candidates"
  ["article_title"]=>
  string(102) "Charles River, Takeda announce scientific collaboration to identify and develop preclinical candidates"
  [2]=>
  string(160) "Together, Charles River and Takeda will launch multiple integrated programs across Takeda’s four core therapeutic areas—oncology, gastroenterology"
  ["short_description"]=>
  string(160) "Together, Charles River and Takeda will launch multiple integrated programs across Takeda’s four core therapeutic areas—oncology, gastroenterology"
  [3]=>
  string(735) "
Together, Charles River and Takeda will launch multiple integrated programs across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience, and rare disease—with the ultimate goal of delivering preclinical candidates 
&#nl
The post Charles River, Takeda announce scientific collaboration to identify and develop preclinical candidates appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(735) "
Together, Charles River and Takeda will launch multiple integrated programs across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience, and rare disease—with the ultimate goal of delivering preclinical candidates 
&#nl
The post Charles River, Takeda announce scientific collaboration to identify and develop preclinical candidates appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(154) "https://www.pharmaceutical-business-review.com/news/charles-river-takeda-announce-scientific-collaboration-to-identify-and-develop-preclinical-candidates/"
  ["blog_url"]=>
  string(154) "https://www.pharmaceutical-business-review.com/news/charles-river-takeda-announce-scientific-collaboration-to-identify-and-develop-preclinical-candidates/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-16 20:18:47"
  ["create_at"]=>
  string(19) "2020-01-16 20:18:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7059"
  ["article_id"]=>
  string(4) "7059"
  [1]=>
  string(76) "Bayer to commercialise Daré’s monthly contraceptive Ovaprene in US"
  ["article_title"]=>
  string(76) "Bayer to commercialise Daré’s monthly contraceptive Ovaprene in US"
  [2]=>
  string(157) "Ovaprene is Daré’s investigational hormone-free monthly vaginal contraceptive, which is under clinical development to prevent pregnancy. Under the "
  ["short_description"]=>
  string(157) "Ovaprene is Daré’s investigational hormone-free monthly vaginal contraceptive, which is under clinical development to prevent pregnancy. Under the "
  [3]=>
  string(608) "
Ovaprene is Daré’s investigational hormone-free monthly vaginal contraceptive, which is under clinical development to prevent pregnancy. Under the exclusive licence agreement, Bayer will commercialise Ovaprene after it is 
&#nl
The post Bayer to commercialise Daré’s monthly contraceptive Ovaprene in US appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(608) "
Ovaprene is Daré’s investigational hormone-free monthly vaginal contraceptive, which is under clinical development to prevent pregnancy. Under the exclusive licence agreement, Bayer will commercialise Ovaprene after it is 
&#nl
The post Bayer to commercialise Daré’s monthly contraceptive Ovaprene in US appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/bayer-contraceptive-ovaprene/"
  ["blog_url"]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/bayer-contraceptive-ovaprene/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-16 20:18:47"
  ["create_at"]=>
  string(19) "2020-01-16 20:18:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7060"
  ["article_id"]=>
  string(4) "7060"
  [1]=>
  string(71) "ViiV Healthcare seeks EMA approval for HIV-1 drug candidate fostemsavir"
  ["article_title"]=>
  string(71) "ViiV Healthcare seeks EMA approval for HIV-1 drug candidate fostemsavir"
  [2]=>
  string(150) "Under the marketing authorisation application (MAA) submitted to the European Medicines Agency (EMA), the company has asked the regulator to review th"
  ["short_description"]=>
  string(150) "Under the marketing authorisation application (MAA) submitted to the European Medicines Agency (EMA), the company has asked the regulator to review th"
  [3]=>
  string(570) "
Under the marketing authorisation application (MAA) submitted to the European Medicines Agency (EMA), the company has asked the regulator to review the potential use of fostemsavir in combination 
&#nl
The post ViiV Healthcare seeks EMA approval for HIV-1 drug candidate fostemsavir appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(570) "
Under the marketing authorisation application (MAA) submitted to the European Medicines Agency (EMA), the company has asked the regulator to review the potential use of fostemsavir in combination 
&#nl
The post ViiV Healthcare seeks EMA approval for HIV-1 drug candidate fostemsavir appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(84) "https://www.pharmaceutical-business-review.com/news/viiv-healthcare-fostemsavir-ema/"
  ["blog_url"]=>
  string(84) "https://www.pharmaceutical-business-review.com/news/viiv-healthcare-fostemsavir-ema/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-16 20:18:47"
  ["create_at"]=>
  string(19) "2020-01-16 20:18:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7061"
  ["article_id"]=>
  string(4) "7061"
  [1]=>
  string(89) "Alnylam initiates rolling submission of NDA for Lumasiran in primary Hyperoxaluria Type 1"
  ["article_title"]=>
  string(89) "Alnylam initiates rolling submission of NDA for Lumasiran in primary Hyperoxaluria Type 1"
  [2]=>
  string(150) "The rolling submission allows completed sections of an NDA to be reviewed by the FDA on an ongoing basis. Specifically, Alnylam has submitted the non-"
  ["short_description"]=>
  string(150) "The rolling submission allows completed sections of an NDA to be reviewed by the FDA on an ongoing basis. Specifically, Alnylam has submitted the non-"
  [3]=>
  string(627) "
The rolling submission allows completed sections of an NDA to be reviewed by the FDA on an ongoing basis. Specifically, Alnylam has submitted the non-clinical components to the 
&#nl
The post Alnylam initiates rolling submission of NDA for Lumasiran in primary Hyperoxaluria Type 1 appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(627) "
The rolling submission allows completed sections of an NDA to be reviewed by the FDA on an ongoing basis. Specifically, Alnylam has submitted the non-clinical components to the 
&#nl
The post Alnylam initiates rolling submission of NDA for Lumasiran in primary Hyperoxaluria Type 1 appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(142) "https://www.pharmaceutical-business-review.com/news/alnylam-initiates-rolling-submission-of-nda-for-lumasiran-in-primary-hyperoxaluria-type-1/"
  ["blog_url"]=>
  string(142) "https://www.pharmaceutical-business-review.com/news/alnylam-initiates-rolling-submission-of-nda-for-lumasiran-in-primary-hyperoxaluria-type-1/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-16 20:18:47"
  ["create_at"]=>
  string(19) "2020-01-16 20:18:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7062"
  ["article_id"]=>
  string(4) "7062"
  [1]=>
  string(65) "NeuroBo Pharmaceuticals and Gemphire Therapeutics complete merger"
  ["article_title"]=>
  string(65) "NeuroBo Pharmaceuticals and Gemphire Therapeutics complete merger"
  [2]=>
  string(158) "The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. Neur"
  ["short_description"]=>
  string(158) "The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. Neur"
  [3]=>
  string(592) "
The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. NeuroBo will focus on advancing the 
&#nl
The post NeuroBo Pharmaceuticals and Gemphire Therapeutics complete merger appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(592) "
The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. NeuroBo will focus on advancing the 
&#nl
The post NeuroBo Pharmaceuticals and Gemphire Therapeutics complete merger appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(118) "https://www.pharmaceutical-business-review.com/news/neurobo-pharmaceuticals-and-gemphire-therapeutics-complete-merger/"
  ["blog_url"]=>
  string(118) "https://www.pharmaceutical-business-review.com/news/neurobo-pharmaceuticals-and-gemphire-therapeutics-complete-merger/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-16 20:18:47"
  ["create_at"]=>
  string(19) "2020-01-16 20:18:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7174"
  ["article_id"]=>
  string(4) "7174"
  [1]=>
  string(34) "MHRA Beta Partner for Virtuosi®"
  ["article_title"]=>
  string(34) "MHRA Beta Partner for Virtuosi®"
  [2]=>
  string(150) "The World’s First Virtual Reality Educational Platform For Sterile Manufacturing Launches Atlanta, GA (January 7, 2020) Quality Executive Partne"
  ["short_description"]=>
  string(150) "The World’s First Virtual Reality Educational Platform For Sterile Manufacturing Launches Atlanta, GA (January 7, 2020) Quality Executive Partne"
  [3]=>
  string(583) "The World’s First Virtual Reality Educational Platform For Sterile Manufacturing Launches Atlanta, GA (January 7, 2020) Quality Executive Partners, Inc. (QxP) is honored to recognize the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for its support during development of Virtuosi®, an on-demand educational platform that leverages the power of virtual reality (VR). A team of five senior sterile experts from MHRA’s GMP Inspectorate participated as QxP’s primary beta partner in the pilot program,...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(583) "The World’s First Virtual Reality Educational Platform For Sterile Manufacturing Launches Atlanta, GA (January 7, 2020) Quality Executive Partners, Inc. (QxP) is honored to recognize the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for its support during development of Virtuosi®, an on-demand educational platform that leverages the power of virtual reality (VR). A team of five senior sterile experts from MHRA’s GMP Inspectorate participated as QxP’s primary beta partner in the pilot program,...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(63) "http://www.realwire.com/releases/MHRA-Beta-Partner-for-Virtuosi"
  ["blog_url"]=>
  string(63) "http://www.realwire.com/releases/MHRA-Beta-Partner-for-Virtuosi"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-16 20:19:30"
  ["create_at"]=>
  string(19) "2020-01-16 20:19:30"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7328"
  ["article_id"]=>
  string(4) "7328"
  [1]=>
  string(67) "Epizyme gets FDA approval for Tazverik to treat epithelioid sarcoma"
  ["article_title"]=>
  string(67) "Epizyme gets FDA approval for Tazverik to treat epithelioid sarcoma"
  [2]=>
  string(150) "Tazverik, a methyltransferase inhibitor, has been approved to treat adults and paediatric patients aged between 16 years and older with metastatic or "
  ["short_description"]=>
  string(150) "Tazverik, a methyltransferase inhibitor, has been approved to treat adults and paediatric patients aged between 16 years and older with metastatic or "
  [3]=>
  string(575) "
Tazverik, a methyltransferase inhibitor, has been approved to treat adults and paediatric patients aged between 16 years and older with metastatic or locally advanced epithelioid sarcoma sarcoma not 
&#nl
The post Epizyme gets FDA approval for Tazverik to treat epithelioid sarcoma appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(575) "
Tazverik, a methyltransferase inhibitor, has been approved to treat adults and paediatric patients aged between 16 years and older with metastatic or locally advanced epithelioid sarcoma sarcoma not 
&#nl
The post Epizyme gets FDA approval for Tazverik to treat epithelioid sarcoma appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(90) "https://www.pharmaceutical-business-review.com/news/epizyme-tazverik-tepithelioid-sarcoma/"
  ["blog_url"]=>
  string(90) "https://www.pharmaceutical-business-review.com/news/epizyme-tazverik-tepithelioid-sarcoma/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-27 15:17:19"
  ["create_at"]=>
  string(19) "2020-01-27 15:17:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7329"
  ["article_id"]=>
  string(4) "7329"
  [1]=>
  string(101) "LB Pharmaceuticals initiates patient dosing in phase 1 study of LB-102 for treatment of schizophrenia"
  ["article_title"]=>
  string(101) "LB Pharmaceuticals initiates patient dosing in phase 1 study of LB-102 for treatment of schizophrenia"
  [2]=>
  string(150) "LB-102 is a novel benzamide designed to be an improved version of amisulpride, a drug successfully used in Europe but unavailable in the United States"
  ["short_description"]=>
  string(150) "LB-102 is a novel benzamide designed to be an improved version of amisulpride, a drug successfully used in Europe but unavailable in the United States"
  [3]=>
  string(644) "
LB-102 is a novel benzamide designed to be an improved version of amisulpride, a drug successfully used in Europe but unavailable in the United States. The ongoing study 
&#nl
The post LB Pharmaceuticals initiates patient dosing in phase 1 study of LB-102 for treatment of schizophrenia appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(644) "
LB-102 is a novel benzamide designed to be an improved version of amisulpride, a drug successfully used in Europe but unavailable in the United States. The ongoing study 
&#nl
The post LB Pharmaceuticals initiates patient dosing in phase 1 study of LB-102 for treatment of schizophrenia appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(154) "https://www.pharmaceutical-business-review.com/news/lb-pharmaceuticals-initiates-patient-dosing-in-phase-1-study-of-lb-102-for-treatment-of-schizophrenia/"
  ["blog_url"]=>
  string(154) "https://www.pharmaceutical-business-review.com/news/lb-pharmaceuticals-initiates-patient-dosing-in-phase-1-study-of-lb-102-for-treatment-of-schizophrenia/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-27 15:17:19"
  ["create_at"]=>
  string(19) "2020-01-27 15:17:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7330"
  ["article_id"]=>
  string(4) "7330"
  [1]=>
  string(118) "Jazz Pharmaceuticals submits NDA for JZP-258 for cataplexy and excessive daytime sleepiness associated with narcolepsy"
  ["article_title"]=>
  string(118) "Jazz Pharmaceuticals submits NDA for JZP-258 for cataplexy and excessive daytime sleepiness associated with narcolepsy"
  [2]=>
  string(150) "The company redeemed its priority review voucher for the NDA submission. JZP-258 is a novel oxybate product candidate with a unique composition of cat"
  ["short_description"]=>
  string(150) "The company redeemed its priority review voucher for the NDA submission. JZP-258 is a novel oxybate product candidate with a unique composition of cat"
  [3]=>
  string(684) "
The company redeemed its priority review voucher for the NDA submission. JZP-258 is a novel oxybate product candidate with a unique composition of cations resulting in 92%, or 
&#nl
The post Jazz Pharmaceuticals submits NDA for JZP-258 for cataplexy and excessive daytime sleepiness associated with narcolepsy appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(684) "
The company redeemed its priority review voucher for the NDA submission. JZP-258 is a novel oxybate product candidate with a unique composition of cations resulting in 92%, or 
&#nl
The post Jazz Pharmaceuticals submits NDA for JZP-258 for cataplexy and excessive daytime sleepiness associated with narcolepsy appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(171) "https://www.pharmaceutical-business-review.com/news/jazz-pharmaceuticals-submits-nda-for-jzp-258-for-cataplexy-and-excessive-daytime-sleepiness-associated-with-narcolepsy/"
  ["blog_url"]=>
  string(171) "https://www.pharmaceutical-business-review.com/news/jazz-pharmaceuticals-submits-nda-for-jzp-258-for-cataplexy-and-excessive-daytime-sleepiness-associated-with-narcolepsy/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-27 15:17:19"
  ["create_at"]=>
  string(19) "2020-01-27 15:17:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}